autologous CAR T cells KITE-197

A preparation of autologous T lymphocytes that have been genetically engineered to express a chimeric antigen receptor (CAR) with an as of yet undisclosed target, with potential immunomodulating and antineoplastic activities. Upon administration, autologous CAR T cells KITE-197 specifically recognize and kill tumor cells expressing the as of yet undisclosed antigen target. This results in a cytotoxic T-lymphocyte (CTL) response against these tumor cells, thereby causing tumor cell lysis.